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Abstract
Dengue viruses (DENV1-4) cause 390 million clinical infections every year, several hundred 
thousand of which progress to severe hemorrhagic and shock syndromes. Preexisting immunity 
resulting from a previous DENV infection is the major risk factor for severe dengue during 
secondary heterologous infections. During primary infections in infants, maternal antibodies pose 
an analogous risk. At the same time, maternal antibodies are likely to prevent induction of 
endogenous anti-DENV antibodies in response to current live, attenuated virus (LAV) vaccine 
candidates. Any effective early life dengue vaccine has to overcome maternal antibody 
interference (leading to ineffective vaccination) and poor induction of antibody responses 
(increasing the risk of severe dengue disease upon primary infection). In a previous study, we 
demonstrated that a non-propagating Venezuelan equine encephalitis virus replicon expression 
vector (VRP), expressing the ectodomain of DENV E protein (E85), overcomes maternal 
interference in a BALB/c mouse model. We report here that a single immunization with a 
tetravalent VRP vaccine induced NAb and T-cell responses to each serotype at a level equivalent 
to the monovalent vaccine components, suggesting that this vaccine modality can overcome 
serotype interference. Furthermore, neonatal immunization was durable and could be boosted later 
in life to further increase NAb and T-cell responses. Although the neonatal immune response was 
lower in magnitude than responses in adult BALB/c mice, we demonstrate that VRP vaccines 
generated protective immunity from a lethal challenge after a single neonatal immunization. In 
summary, VRP vaccines expressing DENV antigens were immunogenic and protective in 
neonates, and hence are promising candidates for safe and effective vaccination in early life.
Introduction
The four serotypes of dengue virus (DENV) are the leading cause of the most important 
mosquito-borne viral disease worldwide, with annual estimates of approximately 390 
million infections (1). The World Health Organization also estimates that up to half a 
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million people are hospitalized with severe dengue disease (Dengue Hemorrhagic Fever/
Dengue Shock Syndrome; DHF/DSS), and among them a large proportion are children (2). 
Children and adults are at increased risk of severe dengue upon a secondary infection with a 
different serotype. In addition, infants born to dengue immune mothers are at an increased 
risk of DHF/DSS during a primary infection, and account for more than 5% of all DHF 
cases (3, 4). This increased risk in infants seems to correlate with maternal antibody titers 
dropping to sub-neutralizing levels, and becoming potentially enhancing (3, 4). At present, 
there are no licensed dengue vaccines available, and the ones in development may not be 
effective in infants.
In addition to the challenges inherent to immunizing early in life, when the immune system 
is suboptimal, additional unique challenges are encountered in the development of dengue 
vaccines. (A) A dengue vaccine must be tetravalent (TV) and induce equivalent and durable 
neutralizing antibodies (NAbs) against all 4 serotypes simultaneously, due to the theoretical 
enhanced risk of severe disease if incomplete immunity is induced. (B) Serotype 
interference has been described among the components of some TV LAV vaccines in 
development. The dominant serotype prevents other serotype(s) from inducing adequate 
responses, resulting in incomplete immunity and the need for additional vaccinations over a 
one year period to achieve a tetravalent response (5). (C) In dengue endemic areas, most 
children are born with maternal antibodies (Abs) to DENV. These Abs protect in the first 
months, but also have the potential to interfere with and reduce the efficacy of LAV. 
Therefore, there is a need for early life vaccines that can induce balanced NAb responses 
after a single immunization given early in life, and that are not subject to maternal antibody 
interference.
Venezuelan equine encephalitis virus replicon particles (VRP) are non-propagating viral 
vectors that can express high levels of an antigen protein after a single round of replication. 
VRP-based vaccines expressing various antigens induced protective immunity in rodent 
models (6-13), and in non-human primates (NHP) (14, 15). A VRP-based dengue vaccine 
candidate is immunogenic and protective in adult mice and NHP (16, 17). Furthermore, 
VRP expressing DENV2 prME was immunogenic in weanling mice even in the presence of 
maternal antibodies that prevented immunization with live virus (16).
Here we hypothesize that the VRP vectors are well suited as an effective early life vaccine 
platform for dengue. First, VRP are propagation incompetent, and therefore safe. Second, 
VRP immunization is not dependent on vector propagation and amplification. Therefore, 
serotype interference is minimized as indicated by balanced responses to the 4 dengue 
serotypes in adult mice and non-human primates. Third, VRP induce strong Th1 immune 
responses, potentially overcoming one of the deficiencies in the neonatal immune response. 
And finally, since VRP contain no DENV antigens, maternal antibodies are less likely to 
interfere with the vaccine, as was demonstrated previously (16).
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Vero81, BHK-21, and C6/36 cells were obtained from the American Type Culture 
Collection (ATCC) and appropriately maintained as described previously (17).
WHO reference DENV strains were used in the neutralization assays: DENV1 WP, DENV2 
S-16803, DENV3 CH53489, and DENV4 TVP-360 (provided by R. Putnak from WRAIR). 
The viruses were propagated no more than three times in C6/36 cells, titrated on Vero cells, 
and stored at -80°C. The mouse-adapted, neurovirulent New Guinea C (NGC) strain of 
DENV2 used for challenge studies (provided by the late Robert Shope, UTMB, Galveston, 
TX) was amplified no more than twice in C6/36 cells and stored at -80°C at a concentration 
of 1×107PFU/ml.
DV1-4 VRP Vaccines
The construction and production of VRP vectors expressing a C-terminal truncated protein 
representing 85% of the E protein (E85) from DENV1-4 as well as their source have been 
described in detail elsewhere (17).
Mice and immunizations
Pregnant and adult BALB/c mice were purchased from Charles River and were housed at 
the Global Vaccines Inc. or at the University of North Carolina. The animals were housed 
and cared for in accordance with the protocols approved by each facility's Institutional 
Animal Care and Use Committees. Pregnant mice were closely observed for date and 
approximate time of delivery. Adult mice (6-8 weeks old) or neonatal mice (7 days old) 
were anesthetized (only adults) and injected in both rear footpads with vaccine or diluent 
(5μl in each rear footpad.
Neutralization assay
Neutralizing antibody titers specific for DENV1-4 were quantified using a flow cytometry-
based neutralization assay on Vero cells, as previously described (17). MAb 2H2 (binds prM 
protein) was used for intracellular staining of dengue-infected cells.
Surface and intracellular staining (ICS)
Mouse spleens were harvested, homogenized, and strained through 40μm cell strainers to get 
single cell suspensions. The CD8/CD4 T cell responses were elicited after splenocytes were 
cultured in RPMI-10 media containing brefeldin A (GolgiPlug, BD Biosciences) with the 
appropriate peptide pool (2 μg/ml) (see figure legends for detail) for 18 h at 37°C. Cells 
were stained for CD8 and CD4 (eBioscience) in PBS at 4°C, fixed and permeabilized in 
Cytofix/Cytoperm (BD). For ICS, fixed cells were stained with antibody specific for IFN-γ 
(eBioscience). Cells were analyzed on an Accuri™ C6 Flow Cytometer (BD). The final 
results were obtained after normalizing the value in each sample by subtracting the value 
obtained in mock-stimulated cells. Spleens harvested from GFP-VRP immunized mice were 
also included as control.
Khalil et al. Page 3













IFN-γ enzyme-linked immunospot (ELISPOT) assay
An IFN-γ ELISPOT assay was performed to measure DENV3 E-specific IFN-γ-secreting 
cells in the popliteal draining lymph nodes of neonatally immunized mice. Mouse IFN-γ 
capture antibody (R&D Systems) was incubated on nitrocellulose membrane plates (96 well; 
Millipore) overnight at 4°C. Single cell suspensions in RPMI-10 (2.5×105 cells per well) 
from popliteal DLN were added after washing the plates. Peptides (see figure legends for 
detail) were added at final concentration of 2 μg/ml for 36 h. IFN-γ spots were developed 
according to manufacturer's protocol (R&D Systems) and the plates scanned by Cellular 
Technologies Ltd. [Shaker Heights, OH].
Challenge
Survival after DENV challenge was studied in mice three weeks after MV and TV neonatal 
immunization. Immunized and PBS control mice were anesthetized and challenged by 
intracranial injection with 5×104 PFU of mouse-adapted strain DENV2 NGC virus. Mice 
wereobserved for 25 days for weight change, morbidity, and mortality. Mice were 
euthanized if their weight dropped below 80% of their initial weight.
Statistical analysis
Neutralization titers and immune cell values were evaluated for statistically significant 
differences by either the ANOVA or Mann–Whitney tests (GraphPad Prism). Statistical 
significance is reported as follows (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
Results
VRP expressing monovalent dengue E85 protein induces a sustained neutralizing 
antibody response after a single immunization
The kinetics of the Nab response after one immunization with DENV3 E85-VRP was 
compared in adult and neonatal mice. Adult and neonatal mice were given a single 
immunization with 1×106 IU of DV3-VRP. Mice were bled at 3, 6, and 13 (15 in neonates) 
weeks post immunization (wpi) (Figures 1A & 1B). A single immunization in both adult and 
neonatal mice induced a NAb response in all animals. In neonates, the NAb titers against 
DENV3 remained below the limit of detection at 3 wpi, increased and peaked at around 6 
wpi and remained relatively stable for up to 15 wpi (last time-point tested). While induction 
of NAbs in adult mice showed similar kinetics, titers were significantly higher than those in 
neonates. A VRP vaccine expressing E85 from a serotype 2 (DV2-VRP) yielded serotype-
specific NAbs in neonates with similar kinetics to DV3-VRP (data not shown).
Neutralizing antibody titers induced by monovalent (MV) and tetravalent (TV) vaccination
To determine whether each serotype VRP vaccine was immunogenic, and whether there was 
serotype interference among the 4 components in the TV formulation, adult and neonatal 
mice were immunized with each MV component separately or in the TV mix, and NAbs 
were measured. In adult mice, two immunizations with TV-VRP induced comparable NAb 
titers to each dengue serotype (Figure 2A-D). In addition, the NAb titers induced by each 
serotype when administered as MV vs. TV vaccine were similar (p>0.2). In neonates, a 
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single immunization with TV vaccine induced NAbs to all 4 serotypes in every animal. Like 
in adult mice, NAb titers for serotypes 1, 2, and 3 (serotype 4 was lost to analysis) were not 
significantly different between the TV and MV formulations, (Figure 2E-H), suggesting that 
serotype interference was minimized when using the VRP vaccine approach.
VRP induces T cell responses to DENV3 E protein in mice immunized with monovalent or 
tetravalent vaccine
To determine whether DENV envelope-specific T-cells are induced upon VRP 
immunization, adult mice were immunized with either 106 IU of DV3-VRP or a TV 
formulation with 106 IU each of the four serotypes. All mice were boosted with the 
homologous vaccine before harvesting spleens 8 days post-boost for ICS. In cells stimulated 
with a pool of DV3 E peptides, we observed IFNγ+ CD8+ T-cell responses against DENV3 
envelope for both MV and TV immunizations, and these did not differ significantly, p=0.49 
(Figure 3A). Furthermore, DENV3 E-specific IFNγ+ CD4+ T cells were induced and were 
not significantly different between MV and TV vaccines (p=0.07). In a separate experiment, 
a similar result was observed (data not shown).
Neonatal mice received a single immunization with 106 IU DV3-VRP (Figure 3B). DLN 
and spleens were harvested on 8 dpi. Due to the limited number of immune cells present in 
neonatal DLN, an IFNγ-ELISPOT assay was performed instead of ICS. We observed that 
both MV and TV immunizations induced similar levels of IFNγ-secreting cells in the 
neonatal DLN (p=0.93). Antigen-specific IFNγ-secreting cell numbers in the spleen were 
reduced; however, they were not significantly different for MV and TV immunized mice 
(p=0.94). Since the harvested immune cells were stimulated with a panel of pooled DENV3 
envelope peptides, we infer that most, if not all, of the IFNγ secreting cells were antigen-
specific T-cells.
Neonatal priming with VRP improves immune responses upon a later adult immunization
Three groups of mice were immunized on d7 post-birth, on d7 & d35, or only on d35. All 
mice received 106 IU DV3-VRP (Figure 4A). On d56, serum was collected for 
neutralization assays. Significantly higher Neut50 titers were observed in mice that had been 
primed as neonates and boosted as adults (GMT = 601) compared to immunization on d7 
only (GMT = 95; p <0.05) The increase after the booster immunization was mostly due to 
the prime, mice immunized on d35 only had reduced NAb titers (GMT = 121; p=0.0519). A 
parallel experiment with DV2-VRP was set up to investigate the CD8 T-cell responses, in 
which the spleens were harvested on day 43. Using ICS, single cell suspensions of 
splenocytes were evaluated for the presence of IFNγ-secreting CD8 T-cells following 
stimulation with a panel of pooled DENV2 E-protein peptides. As seen for the NAb 
response, there was a significantly higher T-cell response in mice receiving two 
immunizations compared to those that only received immunization on d35 only or day 7 
only (Figure 4B).
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A single neonatal immunization with the VRP-based vaccine confers protection from 
dengue challenge
Protection was determined using an intracranial DENV2 challenge model. Neonatal mice 
immunized with TV-VRP, DV2-VRP or PBS were challenged 3 weeks later with a mouse 
brain-adapted DENV2 strain. While all the PBS immunized mice succumbed to challenge 
by day 17, mice receiving either the MV DV2-VRP or the TV vaccine had significantly 
better protection with 5/6 (p=0.0024) and 4/6 (p=0.0018) mice surviving the challenge, 
respectively (Figure 5). There was no significant difference between the MV and TV 
immunized groups. In a separate experiment, weanling BALB/c mice (21 days old) 
vaccinated with 106 IU DV2-VRP were protected (8 out of 9 animals) from a lethal 
challenge at three weeks post-immunization. The control mice immunized with 106 IU HA-
VRP (expressing an irrelevant influenza HA antigen) did not confer any protection (0/8) 
(supplementary figure 1).
Discussion
There is currently no licensed vaccine for dengue, and the vaccine candidates in advanced 
clinical trials do not target children <12-15 months of age. Developing a dengue vaccine that 
can be administered during the first year of life is important for 2 reasons. First, in dengue 
endemic areas, most children are born with dengue maternal antibodies, which are protective 
during the first few months of life. However, these maternal antibodies become a risk factor 
for severe disease via ADE when they wane to sub-neutralizing titers (3, 4). An early life 
vaccine would protect these infants at risk of DHF/DSS. Second, vaccinating early in life in 
endemic regions would have the advantage of vaccinating a population more likely to be 
uniformly DENV-naïve, avoiding having to vaccinate older subjects with differences in pre-
existing immunity, which may affect vaccine-induced immunity in unknown ways.
Our study is the first to address the challenges of immunizing against dengue early in life, 
and to demonstrate that the VRP vaccine platform is an effective early life dengue vaccine 
candidate. The present study demonstrates that VRP vaccines can induce NAbs in neonatal 
mice after a single immunization and that the titers remain stable until at least 15wpi. 
Although these titers were reduced at all time-points post-immunization compared to those 
in adult mice, this finding was not surprising, as the neonatal immune response is known to 
be weaker (18-21), resulting in lower serum antibody titers (22, 23) of shorter duration (24, 
25).
Dengue vaccines in development seek to induce robust NAbs to all 4 serotypes (26). 
However, results from the first dengue phase IIb efficacy trial suggest that cell-mediated 
immunity may be needed in a dengue vaccine (27), and a recent study suggests that the 
DENV-specific CD8+ T-cell response in humans correlates with protection in an HLA-
specific manner (28). VRP vaccines induce robust CD8+ CTL responses in adult mice to 
other antigens (29). Even though neonates induce significantly reduced CTL responses (21), 
our studies showed dengue-specific IFNγ-secreting cells in the DLN of neonatal mice, 
which we infer to be predominantly CD8+ (Figure 3B). This is based on observations in 
adult mice, which showed an approximately 10-fold higher quantity of dengue-reactive 
CD8+ cells compared to CD4+ cells (Figure 3A). Direct comparison between neonates and 
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adults in the current study is difficult, because there was only a single neonatal 
immunization, while adult mice were immunized twice. However, this is the first study to 
our knowledge that shows induction of a DENV-specific T-cell response in neonatal mice 
after a single immunization. We predict that addition to the immunization cocktail of VRP 
expressing DENV NS3 and/or NS5, major targets of T-cell responses, will result in a 
stronger antigen-specific CD8+ T-cell response.
The induction of equivalent NAb responses has been a major challenge for vaccines based 
on replicating antigens, where different rates of replication or immunodominance result in 
unbalanced responses (5, 30). In a TV, non-propagating VRP vaccine, the 4 components 
presumably have similar replication rates, reducing the chances of serotype interference. 
Indeed, we show here a VRP-based TV vaccine induced equivalent titers to each serotype 
after a single dose in neonates, and the NAbs induced were comparable to those induced by 
each individual component when tested as a MV vaccine.
It is possible that the serotype-specific NAbs measured 3 weeks after TV vaccination could 
be attributed to cross-reactive NAbs induced by the dominant serotypes. This is unlikely for 
two reasons. First, studies in adult mice indicate that MV E85-VRP vaccines predominantly 
induce homologous NAbs with very low amounts of cross-reactive NAbs (data not shown). 
Second, since cross-reactive NAbs induced by one serotype are short-lived (31, 32), 
measuring NAbs to all 4 serotypes long after immunization reflects a true TV response. This 
was indeed demonstrated 73-weeks after immunization of adult mice with two doses of TV 
VRP vaccine expressing DENV1-4 prME (supplementary figure 2).
A previous study demonstrated that a DENV-VRP vaccine was not subject to otherwise 
interfering maternal antibodies when it was used to immunize weanling mice born to 
DENV-immune dams (16). Maternal antibody interference is one of the most important 
obstacles to developing an early life dengue vaccine, especially because LAV are likely to 
be ineffective at this age due to maternal antibodies interfering with the replication of the 
vaccine strains.
Reducing the risk of DHF in early life after a single immunization will allow opportunities 
for a second immunization to further improve the immune response. Anti-vector immunity is 
undetectable-to-low after a single VRP immunization in NHP, and does not prevent a 
second VRP immunization from having a booster effect on dengue-specific NAbs (17). This 
suggested that infants primed with a VRP vaccine could be safely and effectively boosted 
with a second dose of a VRP vaccine. Neonatal mice primed on d7 appear to produce more 
NAb after a boost on d35 than animals that received a single inoculation on d35 (p=0.0519). 
Similarly, the CD8+ T-cell response is significantly higher when the mice were first primed 
as neonates (p=0.0498). Although these p-values hover around the limit of significance, we 
feel that immunizing neonatal animals not only will have a salutary effect on protection of 
neonates as maternal NAb wanes, but also will prime an improved boost response going 
forward. The second immunization as an adult could utilize a homologous or heterologous 
vaccine platform to broaden and strengthen the immune response. Although anti-vector 
immunity is a concern that remains to be addressed in humans, studies in adult mice 
(unpublished data) and macaques (17), have shown anti-VEE NAbs do not have any 
Khalil et al. Page 7













significant effect on the induction of NAbs to vaccine antigens. Another potential concern is 
the chance of in vivo recombination if vaccination occurs at the same time as infection with 
wild type virus. This event is highly unlikely to result in recombinant virus of more 
virulence than the wild-type infecting virus itself.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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DENV3-VRP vaccine induces neutralizing antibody response after a single immunization in 
neonates and adult mice. Adult mice were anesthetized before immunization by 
intraperitoneal (i.p.) injection with a 4/1 mixture (vol/vol) of ketamine (50 μg/g body 
weight) and xylazine (15 μg/g body weight). (A) Six adult BALB/c mice (6 weeks old) were 
immunized with 1×106 IU of monovalent DV3 -VRP and neutralizing antibody titers were 
measured in the sera at 3, 6, and 13 weeks post-immunization. (B) Six neonatal mice were 
immunized on day 7 after birth with 1×106 IU of monovalent DV3 -VRP. Three, 6, and 15 
weeks after the immunization, neutralization antibody titers were measured in the sera of the 
immunized mice. Note: There were only five samples for 6 weeks time-point. Data are 
presented as 50% neutralization titers (Neut50) (GMT +/- 95% CI). The limit of detection for 
this assay was 10.
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Serotype-specific Nab titers induced by each MV and TV vaccine in adult and neonatal 
mice. (A-D) Eight adult BALB/c mice per group were immunized and boosted (under 
anesthesia) 4 weeks later with 2×106 IU of each monovalent vaccine, DV1-VRP, DV2-VRP, 
DV3-VRP, or DV4-VRP or with a tetravalent cocktail of the above four VRP vaccines at 
106 IU each. NAbs were determined at 3 weeks post boost. Graphs A-D represent Neut50 
titers against serotypes 1-4 respectively. Each graph includes NAbs induced by the 
monovalent (white bars) or the tetravalent (black bars) vaccine. Data are presented as GMT 
+/- 95% CI. The limit of detection for this assay was 10. (p values: DENV1 = 0.59; DENV2 
= 0.24; DENV3 = 0.24; DENV4 = 0.26). (E-H) Neonatal mice were immunized on day 7 
after birth with 1×106 IU of either monovalent DV1-VRP (N=7), DV2-VRP (N=9) or DV3-
VRP (N=6). A tetravalent immunization with 1×106 IU of each DV1-, DV2, DV3, and 
DV4-VRP expression vectors were administered to a group of 6 neonatal mice. Neut50 titers 
were determined at 15 weeks post immunization. (p values: DENV1 = 0.95; DENV2 = 0.52; 
DENV3 = 0.01). Monovalent DV4-VRP immunization data was lost to analysis (Figure 2H).
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Induction of DENV E-specific cell-mediated immunity (CMI) after monovalent and 
tetravalent VRP immunization in adult and neonatal mice. (A) CD4+ and CD8+ T cell 
responses in adult mice. Adult BALB/c mice (4 per group) were immunized and boosted 
(under anesthesia) 4 weeks later with 106 IU of either monovalent DV3-VRP or a tetravalent 
cocktail of 106 IU each of DV1-VRP, DV2-VRP, DV3-VRP, and DV4-VRP (TV-VRP). 
Splenocytes were obtained 8 days after booster immunization and stimulated with peptide in 
vitro. Overlapping peptides derived from DENV3 E protein were used (68 DENV3 E 
peptides, BEI NR-9228), which were resuspended in DMSO and pooled. Cells were stained 
by ICS for IFNγ after surface staining of CD4 and CD8. Data were normalized to mock-
stimulated splenocytes of each individual mouse. (B) CMI after a single immunization in 
neonatal mice. Six neonatal mice per group (five in tetravalent DLN group) were immunized 
with 106 IU of either monovalent DV3-VRP or a tetravalent cocktail of 106 IU each of DV1-
VRP, DV2-VRP, DV3-VRP, and DV4-VRP (TV-VRP). At 8 days post immunization 
spleens and DLN were harvested. The two popliteal DLNs from each mouse were 
combined. For immune cell stimulation, 68 DENV3 E peptides obtained from BEI 
(NR-9228) were individually resuspended in DMSO, and pooled in three panels: A (peptides 
1 to 23), B (peptides 24 to 46), and C (peptides 47 to 68). Unpublished observations in adult 
mice showed the highest immune response to E was in peptide pool B (includes amino acid 
sequence from 174 to 343), DLN immune cells were stimulated with E peptide pool B. 
IFNγ-producing cells were quantified by ELISPOT assay. Data were normalized to mock-
stimulated DLN cells of each individual mouse. All results were graphed as mean +/- SEM.
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Neonatal immunization with VRP vaccine primes robust neutralizing antibody and T-cell 
responses. (A) Neutralizing antibody responses – Three groups of mice were immunized 
with 106 IU of DV3-VRP as follows: on day 7 after birth, groups 1 (n=6, white bars) and 
group 2 (n=6, black bars) received VRP vaccine, and group 3 (n=5, gray bars) received 
diluent (PBS + 0.1%HSA). On day 35, groups 2 and 3 received VRP vaccine, and group 1 
received diluent (all under anesthesia). On day 56, all groups were bled and Neut50 titers vs. 
DENV2 were determined. Bars represent GMT +/- 95% CI. (B) T-cell responses – Three 
groups of mice were immunized with 106 IU of DV2-VRP as described in figure 4A. 
Groups 1 and 2 had 3 mice each and group 3 had 4 mice. On day 43 (8 days post boost) 
splenocytes from all mice were harvested followed by stimulation with DENV2 E-protein 
peptide cocktail (67 peptides, BEI NR-507), surface staining for CD8, and intracellular 
cytokine staining for IFNγ. Data were normalized to mock-stimulated splenocytes of each 
individual mouse, and expressed as number of CD8+ T cells per 106 cells. Results were 
graphed as mean +/- SEM. * indicates p<0.05.
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VRP expression vector immunization is protective in mice after a single immunization on 
day 7. Six 7-day-old neonatal BALB/c mice were immunized with 106 IU of either 
monovalent DV2-VRP or a tetravalent cocktail of 106 IU each of DV1-VRP, DV2-VRP, 
DV3-VRP, and DV4-VRP (TV-VRP). Six control neonatal mice were immunized with 
diluent. Three weeks after immunization, all mice were challenged intracranially (under 
anesthesia) with 5×104 PFU of a mouse-adapted, neurovirulent New Guinea C strain of 
dengue virus serotype 2. The mice were observed daily for 25 days after challenge. Results 
are presented as percent survival.
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